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Abstract
Background: In complex regional pain syndrome type 1 (CRPS1) pro-inflammatory
mediators and vascular changes play an important role in the sustained development and
outcome of the disease. The aim of this study was to determine the involvement of
vasoactive substances endothelin-1 (ET-1) and nitric oxide (NO) during early chronic CRPS1.
Methods: Included were 29 patients with CRPS 1 who were diagnosed during the acute
stage of their disease and observed during follow-up visits. Disease activity and impairment
were determined and artificial suction blisters were made on the CRPS1 and the
contralateral extremities for measurements of IL-6, TNF-α, ET-1 and nitrate/nitrite (NOx).
Results: The levels of IL-6, TNF-α and ET-1 in blister fluid in the CRPS1 extremity versus
the contralateral extremity were significantly increased and correlated with each other,
whereas NOx levels were decreased.
Conclusion: The NOx/ET-1 ratio appears to be disturbed in the intermediate stage of
CRPS, resulting in vasoconstriction and consequently in a diminished tissue blood
distribution.
1. Background
Complex regional pain syndrome (CRPS) is a painful dis-
order which mainly occurs as a complication after surgery
or trauma, and the main characteristics are continuous
pain, marked changes in tissue blood flow and skin sur-
face temperature, oedema and sweating, movement disor-
ders and trophic changes of the skin [1,2]. The severity of
the symptoms is disproportionate to the initial event. The
diagnosis of CRPS is entirely based upon clinical criteria
[3,4]. In the Netherlands, the incidence of CRPS1 is
approximately 2.6% for different fractures, which results
in approximately 5100 new patients yearly, of whom a
substantial part will not recover completely [5-7]. The
female to male ratio is approximately 3:1, with a median
age of 52.7 years at onset [7]. The pathophysiology of
CRPS1 is not unravelled yet, but growing evidence indi-
cates the involvement of an exaggerated inflammatory
processes. Both central and peripheral mechanisms have
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tion leading to exacerbation of pain is thought to result
from neuroimmune activation of cells in the peripheral
nervous system [5]. During the neurogenic inflammation,
neuropeptides [8] and cytokines and other mediators are
released [9]. This leads to a so-called 'warm dystrophy'
with signs of inflammation such as redness, increased skin
temperature, loss of function and pain [4,5,10].
During the chronic, disabling stage of the disease, in gen-
eral the following changes occur: i) signs of extravasation,
and oedema changes into atrophy, ii) regional blood flow
declines, and iii) increased skin temperatures change into
diminished temperatures. Permanent damage of nerve
endings can lead to less endothelium-dependent vasodila-
tion and result in a diminished regional blood distribu-
tion, the so-called 'cold dystrophy' [11,12]. Both
continuous pain and signs of 'cold dystrophy' can lead to
assumed irreversible disuse. The contribution of endothe-
lial derived factors could be crucial; endothelin-1 (ET-1) is
a proven potent vasoconstrictive agent that is also
believed to affect hyperalgesia [13], muscle weakness and
movement disorders [14], and oedema [15].
In contrast to skeletal muscle resistance vessels, ET-1 con-
tributes to the maintenance of skin microvascular tone
through both ETA and ETB receptor-mediated vasocon-
striction [16]. The initially produced pro-inflammatory
cytokines tumour necrosis factor alpha (TNF-α) and inter-
leukin-6 (IL-6) also play an important role in the initial
and intermediate phases of the disease [9,17]. TNF-α is
known to decrease eNOS mRNA levels by increasing the
rate of mRNA degradation [18,19]. In the human forearm,
TNF-α promotes ET-1 production [20]. On the other
hand, ET-1 also promotes TNF-α and IL-6 production in
skin-derived mast cells [21], one of the cells which seem
to play a prominent role in the acute phase of CRPS1 [22].
The present study aimed to investigate the involvement of
the vasoactive substances ET-1 and nitric oxide (NO) in
intermediate/cold type CRPS1 in relation to inflamma-
tory mediators.
2. Methods
2.1. Subjects
For this study 29 patients (6 males, 23 females; mean age
48 ± 11.3 (SD) years) with CRPS1 in one hand according
to the criteria of Bruehl [3], were included. The patients
had a mean duration of their disease of 2.8 ± 1.4 (SD)
years, all being in the intermediate phase between the
acute inflammatory stage and the early atrophic stage.
The mean disease activity of the patients was 35 on a scale
of 0–100, calculated using the impairment sum score
according to Oerlemans [23], representing a low to
medium disease activity.
The Medical Ethics Committee of the Erasmus MC
approved the study protocol (MEC 2004-159). The
research was carried out in accordance with the Declara-
tion of Helsinki (2000) of the World Medical Association
and written informed consent was obtained from all par-
ticipants.
2.2. Blister fluid collection
Artificial blisters were induced by means of a suction
method [9,17,24-27]. A 3-hole (5 mm diameter per hole)
skin suction chamber was positioned on the skin of the
upper extremity, on the dorsal side of the involved hand
and on the flexor side of the contralateral forearm. The lat-
ter site was used in all our previous studies to reduce the
inconvenience for the patient and to enable a comparison
between our studies [5,9,17,22,28,29].
A vacuum of 300 mm Hg negative pressure was applied
with an Atmoforte 350A aspirator pump (ATMOS Mediz-
intechnik, Lenzkirch, Germany), which was reduced after
15 minutes to 250 mm Hg and again, 15 minutes later,
reduced to 200 mm Hg. This negative pressure was main-
tained until blisters containing sufficient fluid had been
developed, but not longer than 2.5 hours. The contents of
the blisters were punctured and pooled from each side
into a 1.5 ml Eppendorff conical polypropylene tube and
centrifuged for 5 minutes at 1600 × g. The mean recovery
of supernatants from control blisters was 144 ± 17 (±
S.E.M.) µl fluid, and 106 ± 14 µl blister fluid from the
CRPS1 side. All samples were stored in 1 ml conical poly-
propylene tubes at -80°C until analysis.
2.3. Measurements of cytokines
In order to determine the contribution of pro-inflamma-
tory cytokines to the disease activity, both IL-6 and TNF-α
were determined [9,17]. Blister fluid samples were diluted
1:4 in appropriate calibrator diluent assay buffer for the
direct measurement of cytokines. Cytokine assays were
performed following the manufacturer's protocol (Pelik-
ine™ human ELISA compact kits for IL-6 (cat. no. M1906)
and TNF-α (cat. no. M1920), Sanquin, Amsterdam, The
Netherlands). The standard curve ranges and mean calcu-
lated zero signal plus 3 SD for IL-6 were 0–450 pg/ml and
0.2 pg/ml, respectively; and for TNF-α 0–1000 pg/ml and
1 pg/ml, respectively. The requested solutions were pro-
vided with the ELISA compact kits and additional tool kits
(Pelikine-Tool™ set (cat. no. M1980), Sanquin, Amster-
dam, The Netherlands). Following the manufacturer's
step-by-step instructions, at the end of the procedure the
absorbance per well was measured at 450 nm with a
Medgenix ELISA reader. Sample concentrations were cal-Page 2 of 8
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and the Softmax® software of the reader.
2.4. Measurement of endothelin-1
ET-1 concentrations were determined in paired blister
fluid samples which were available for 22 patients. Blister
fluids were diluted 1:2 in appropriate diluent assay buffer.
An ELISA-based commercial assay kit was purchased from
R&D Systems (cat. no. QET00, Abingdon, UK). The Quan-
tiGlo ET-1 chemiluminescent immunoassay is a solid
phase ELISA designed to measure ET-1 levels in human
fluids without extraction procedures. It contains synthetic
human ET-1 and antibodies raised against the synthetic
factor, which has been shown to accurately quantitate
human ET-1. A microplate luminometer was used to
measure the intensity of light emitted in RLUs (relative
light units). The standard curve ranged from 0–1000 pg/
ml. Raw data were transferred to a personal computer in
which a log concentration-logit RLU equation was per-
formed after which sample concentrations were calcu-
lated. The minimal detectable concentration was 0.16 pg/
ml.
2.5. Measurement of nitric oxide
Sufficient remaining sample volume was available from
17 paired blister fluid samples to perform the assay proce-
dure for the quantitative determination of nitrate and
nitrite concentrations. Samples were diluted 1:1 in appro-
priate diluent assay buffer. A complete assay kit was
obtained from R&D Systems (cat. no. DE1500, Abingdon,
UK). This assay determines NO based on the enzymatic
conversion of nitrate to nitrite by nitrate reductase. The
reaction is followed by a colorimetric detection of nitrite
as an azo dye product of the Griess reaction. At the end of
procedure the chromophoric azo derivative which
absorbs light at 540 nm is detected in a Medgenix ELISA
reader, after which sample concentrations are calculated
using the appropriate standard calibration line by means
of the Softmax® software of the reader. The standard curve
ranges for nitrite and nitrate were respectively 0–200 and
0–100 nmol/ml and the minimal detectable concentra-
tions were respectively 0.22 and 0.54 nmol/ml. Sample
concentrations were expressed as total NOx in nmol/ml.
2.6. Statistical analysis
The Wilcoxon signed ranks test was used for comparisons
between measurements in blister fluid obtained from the
CRPS1 and the contralateral extremity. Correlation coeffi-
cients between different parameters were determined by
the Spearman's test for untransformed data. SPSS (version
14) for Windows was used and the significance level was
set at p < 0.05.
3. Results
Blister fluid
Pro-inflammatory cytokines IL-6 and TNF-α and vasoac-
tive ET-1 and NOx were determined in blister fluid
obtained from the involved CRPS1 limb and the contra-
lateral limb.
In Figures 1 and 2 the distributions of blister concentra-
tions have been plotted as a correlation between CRPS1
samples (Y-axis) and contralateral samples (X-axis). Suc-
cessively (Fig. 1a) IL-6, (Fig. 1b) TNF-α, (Fig. 2a) ET-1 and
(Fig. 2b) NOx are displayed. In each plot the straight line
indicates per definition a CRPS to contralateral ratio of
1.00 in case no difference was observed. Both in the IL-6,
TNF-α and ET-1 distribution plots, the main number of
data-points are located in the upper-left triangle, indicat-
ing a CRPS to contralateral ratio above 1.00. On the con-
trary, in the NOx distribution plot, the main number of
data points are located in the lower-right triangle, indicat-
ing a CRPS to contralateral ratio less than 1.00.
Box plots of these data, indicating the median, 25–75%
interval and the ranges of values, excluding outliers are
presented in Figures 1c and 2c.
The Wilcoxon signed ranks test was used to assign differ-
ences in paired samples (blister fluid obtained from the
CRPS1 and the contralateral extremity in the same
patient).
Increments in the paired sample tests of IL-6, TNF-α and
ET-1 were significant (p-values of 0.001, 0.003 and 0.002,
respectively), whereas NOx in paired samples was signifi-
cantly decreased (p-value 0.044).
Spearman's correlation coefficients between blister fluid
parameters were determined. Significant correlations
between IL-6, TNF-α and ET-1 were found (0.79, 0.44 and
0.67 for IL-6/TNF-α, IL-6/ET-1 and TNF-α/ET-1, respec-
tively and p-values of p < 0.001, p = 0.039 and p = 0.001,
respectively).
4. Discussion
This is the first study to investigate levels of ET-1 and NOx
in blister fluids obtained from CRPS1-involved extremi-
ties. Apart from a study comparing ET-1 with disease
severity in the skin of psoriatic patients [30], only Eisen-
berg et al. have investigated the possible contribution of
ET-1 in CRPS [31]. In that study, ET-1 concentrations were
determined in venous plasma from the contralateral limb
of CRPS1 patients and did not differ significantly from
values found in patients with other painful conditions
and in healthy controls. The ET-1 levels found in controls
and patients (mean 2.7 and 3.2 pg/ml) were, however,
much higher than those reported in the literature [32,33].Page 3 of 8
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Distribution of IL-6 and TNF-αFigure 1
Distribution of IL-6 and TNF-α. Distribution of a) IL-6 data and b) TNF-α data from 29 CRPS patients, from both the 
involved and the contralateral extremity. In each plot, the straight line indicates per definition a CRPS to contralateral ratio of 
1.00 in case no difference was observed. Values are plotted on logarithmic scales. c) Box plots of these data, indicating the 
median, 25–75% interval and the ranges of values, excluding outliers. The Wilcoxon signed ranks test was used to assign differ-
ences in paired samples (blister fluid obtained from the CRPS1 and the contralateral extremity in the same patient).
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Distribution of Endothelin 1 and Nitric OxideFigure 2
Distribution of Endothelin 1 and Nitric Oxide. Distribution of a) ET-1 data from 22 CRPS patients and b) NOx data from 
17 CRPS patients. In each plot, the straight line indicates per definition a CRPS to contralateral ratio of 1.00 in case no differ-
ence was observed. Values are plotted on linear scales.c) Box plots of these data, indicating the median, 25–75% interval and 
the ranges of values, excluding outliers. The Wilcoxon signed ranks test was used to assign differences in paired samples (blister 
fluid obtained from the CRPS1 and the contralateral extremity in the same patient).
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regarded as a laboratory marker for CRPS. The mean dis-
ease duration of their CRPS patients was 2 years, with a
study population of relatively young patients (mean 30
years) and a male/female ratio of 2/1 [31]. These charac-
teristics were not comparable with our study, in which
age, duration of CRPS1 and the male/female ratio were
much more comparable with demographic characteristics
commonly found in the literature. In general, the main
peak in the development of CRPS is seen at the age of 52
years and the male/female ratio is between 1:3 and 1:4.
Kuryliszyn-Moskal et al. found synovial ET-1 levels of
15.5 pg/ml [34] and similar serum levels [35]. Although
the ET-1 levels we found in blister fluid (3.2 pg/ml) might
be diminished due to interstitial dilution, we believe that
interstitial levels better reflect local processes in CRPS1
than plasma measurements. This is confirmed by the find-
ing of high ET-1 concentrations in blister fluids at wound
regions of burn patients [36].
The role of NO in CRPS has not yet been investigated,
although increased NO production from interferon-γ
stimulated peripheral blood monocytes obtained from
CRPS patients has been observed, in patients with appar-
ently active disease [37]. We found an inverse relationship
between ET-1 and NOx in blister samples. This has also
been observed in vascular homeostasis where endothe-
lium dysfunction plays a prominent role [38]. In venous
plasma of patients with erectile dysfunction, significantly
increased ET-1 and decreased NO levels were found [32].
In pathological situations circulating pro-inflammatory
cytokines induce the expression of iNOS and ET-1 in
smooth muscle cells, also downregulating endothelial
eNOS expression, resulting in an elevated ET-1 produc-
tion and a decrease of NO [18,39]. This was observed in
our study: a significant increase of IL-6 and TNF-α, which
causes a marked increase of ET-1 and a slight but signifi-
cant decrease of NOx. These results confirm the findings
of Munnikes et al. who studied patients with an interme-
diate duration of CRPS (median 20 months) and also
found a significant elevation of IL-6 and TNF-α in the
involved extremity compared with the uninvolved
extremity [29]. That group consisted of 25 patients who
had significantly improved on volume difference, AROM,
VAS and McGill Pain Questionnaire, which makes their
group comparable to our patients with a Impairment Sum
Score [40] of 35. Thus there is increasing evidence for the
role of proinflammatory cytokines in the initiation and
development of CRPS. A longitudinal study is needed that
follows selected CRPS patients from the acute to the
chronic stage to determine the precise involvement of
inflammatory cytokines in the disease activity.
Disuse during chronic CRPS is a common phenomenon.
Vasoconstriction is usually followed by local reductions in
blood flow [11,12]. It is unclear what the effect of disuse
on the production of ET-1 and NO could be, but the
plasma NOx concentration in healthy young humans sig-
nificantly increases after exercise, with a significant
decrease of ET-1 [41]. In healthy subjects, the physiologi-
cal role of ET-1 in nonworking muscles during exercise
has been described [42]. In healthy women, the ET-1
plasma concentration increases with age, which could be
significantly counteracted after exercise [43]. Animal stud-
ies have shown that endogenous ET-1 participates in the
sustained development of the disease in the redistribution
of tissue blood flow [44].
In a previous study we observed that treatment with anti-
TNF-α initiates recovery during the inflammatory stage of
CRPS1 [17]. The effect of this intervention on the release
of ET-1 and NOx is still unclear. Assuming a diminished
blood flow, inhibition of the NO synthase is not advisa-
ble; on the contrary, NO donors should be supplemented
[45]. Besides the smooth muscle constrictive effects of ET-
1, hyperalgesia and pain could also be the result of ET
receptor stimulation. Therefore, specific ETA receptor
antagonists (such as atrasentan) could provide remission
[46]. In pulmonary arterial hypertension, after treatment
with the ET receptor antagonist bosentan, the suppression
of NO synthesis was abolished and reversed to normal
values of controls [47].
During the acute stage of CRPS1 large amounts of NO will
be formed through activation of the inducible NO syn-
thetase (iNOS). In that stage, the blood distribution has
been increased which causes an increase of local skin tem-
perature. In the endothelial cell NO will be formed from
L-arginine through eNOS activation. Formation of NO
could also occur after receptor stimulated activation of
constitutive NOS (cNOS) or activation of neuronal NOS
(nNOS) in nerve endings. In all cases this will result in
increased vasodilation [48]. TNF-α counteracts the activa-
tion of eNOS [19], whereas induction of iNOS in smooth
muscle cells will be stimulated to generate NO [38]. In the
trophic phase of CRPS1 there will be a decline in the con-
tribution of inflammatory mediators. Consequently, in
combination with disuse of the extremity, less NO could
be generated, resulting in diminished basal relaxation and
retarded blood distribution, after which signs of the 'cold
dystrophy' will become apparent.
5. Conclusion
In the vascular system a clear crosstalk exists between the
NO and the ET-1 system. It seems that this interrelation-
ship also exists in CRPS. It is obvious that NO functions as
a controlling mechanism against ET-1-induced vasocon-
striction. The stage of the disease, the acute or inflamma-Page 6 of 8
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2006, 7:91 http://www.biomedcentral.com/1471-2474/7/91tory phase, or the chronic and/or trophic phase,
determines the involvement of inflammatory cytokines
which could promote ET-1 production, leading to vaso-
constriction and consequently to a diminished tissue
blood distribution. A longitudinal study following CRPS
patients during the course of the disease is needed to
investigate the NOx/ET-1 ratio as an indicator of vascular
involvement.
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